Answers are grounded in this paper and cite their sources.
OBJECTIVES: To evaluate the efficacy of high-flow nasal cannula (HFNC) compared with conventional oxygen therapy (COT) in adults with de novo acute hypoxemic respiratory failure (AHRF) using a meta-analysis with trial sequential analysis (TSA). DATA SOURCES: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from database inception to April 7, 2026. STUDY SELECTION: Randomized controlled trials (RCTs) comparing HFNC with COT in adults with de novo AHRF. DATA EXTRACTION: Two investigators independently performed study selection, data extraction, risk-of-bias assessment, and certainty assessment, with discrepancies resolved through discussion. DATA SYNTHESIS: A total of 13 RCTs involving 4294 patients were included in the analysis. Compared with COT, HFNC was associated with a lower risk of intubation (Risk ratio [RR], 0.88; 95% CI, 0.78-0.99; low certainty), but not mortality (RR, 0.96; 95% CI, 0.83-1.10; moderate certainty). TSA indicated that the cumulative evidence was insufficient to establish a conclusive effect for either outcome. Although HFNC was associated with a statistically significant reduction in hospital length of stay (mean difference, -0.84 d; 95% CI, -1.26 to -0.43; low certainty), the clinical importance of this reduction remains uncertain. No significant differences were observed in escalation of therapy (RR, 0.87; 95% CI, 0.75-1.01; very low certainty), ICU admission (RR, 0.84; 95% CI, 0.50-1.39; very low certainty), or ICU length of stay (mean difference, -0.10 d; 95% CI, -0.82 to 0.61; very low certainty). CONCLUSIONS: In adults with de novo AHRF, HFNC may reduce the need for endotracheal intubation but probably does not improve survival compared with COT.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: